Drug intelligence / Profile preview

Triple Intrathecal Therapy

Development stage: Unknown
Modality: Small Molecules
Administration: Intrathecal

Overview

Triple Intrathecal Therapy (TIT) is a combination chemotherapy regimen typically comprising methotrexate, cytarabine, and hydrocortisone. It is administered directly into the cerebrospinal fluid (intrathecally) for the prophylaxis and treatment of central nervous system involvement in various hematologic malignancies, such as acute lymphoblastic leukemia, acute myelogenous leukemia, and myelodysplastic syndromes. Methotrexate acts as a folic acid antagonist, cytarabine as an antimetabolite inhibiting DNA synthesis, and hydrocortisone as a corticosteroid with anti-inflammatory and antineoplastic effects.

Targets

DNA polymerase familyGR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Triple Intrathecal Therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triple Intrathecal Therapy.

Explore the full profile